Drug manufacturer BMS updated its 340B contract pharmacy restrictions to require pharmacies to re-register by June 21 and add additional requirements.

BMS Requires Re-Designation of 340B Contract Pharmacies and New Requirements Intended to Prevent Alternative Distribution Models

Bristol Myers Squibb (BMS) announced updates to its conditions on pharmaceutical sales involving contract pharmacies, requiring registered sites to be [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.